Great results with anitocel , safety profile seems good too. Excited to have more data in the future !

CONGRESS | #EHA25 | PRESENTATION Lisa Leypoldt UKE Hamburg shares findings from the PhII GMMG-CONCEPT trial of Isa-KRd in high-risk patients with NDMM (n = 98). Post-consolidation MRD negativity rate at 10-5 was 74.8% in transplant-eligible patients (n = 219), sustained to 1 year

Key Myeloma therapy update for 2025 1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd). 2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use.

#IMS25 In my mind, this will be the slayer of ASCT more than any other #MMsm regimen... Excellent Tec-DVR & Tec-DR data [1x weekly Velcade & lots of IVIG 👏] in NDMM from MajesTEC-5 Marc S. Raab 100% ORR, 100% MRD neg across the board. This is what we hope for with induction!

Updates from MajesTEC-5: Continue to see unprecedented mrd negativity rates after just 6 cycles of teclistamab + Dara-R and +\- bortezomib. Pretty clear that bortezomib thus far not offering benefit. Is transplant really needed either? Infection rates a bit concerning with short

What's going to be different with the new IMWG response criteria? Main changes: - FLC >=10 mg/dL with abnormal ratio takes precedence over urine (but urine is not gone) - No more sCR - Bone marrow to confirm CR can be performed +/- 6 weeks from blood testing. - 24-hour urine at

#IMS25 and the ones physically administering SC dara over several minutes, mL by mL 🙏🏽 SQ isatuximab via OBI (on-body injection) will be fascinating to see in action (⬇️ time for pts, nurses, and ?PharmDs), but I suspect a learning curve for all of us as we learn to use it!

Xavier Leleu, MD, PhD, chaired a panel on optimizing 1L quadruplets in NDMM, including dose optimization & on-body administration. 1L anti-CD38 antibody quads should be considered for ALL patients who can tolerate them, the panel said. #IMS25

The future is bright! ⁦Myeloma Society⁩ #IMS25 #mmsm

Xavier Leleu, MD, PhD, gave a moving tribute to Frank Bridoux, MD, PhD, friend & colleague at the University Hospital Poitiers. Dr. Bridoux’s expertise included cast nephropathy & glomerulopathies, and seminal contributions in MGRS/MGCS. #IMS25

CONGRESS | IMS 2025 | PRESENTATION Arthur Bobin, Université de Poitiers, presented results from the multicenter phase II IsoSoCut (IFM 2022-05) study evaluating SC isatuximab plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple

👏 👏

Thanks so much IACH & Mohamad Mohty for this beautiful myeloma session, highlighting patients’ confort and nurses work! Very honored to share the stage with my dear nurse colleagues from CHU de Poitiers #myeloma #IACH #mmsm

All the major risk stratification models for myeloma, MGUS, SMM, WM, amyloid in one place! Open Access! Leukemia Journal Saurabh Zanwar nature.com/articles/s4137…

Celebrating 35 years of academic excellence! The IFM has led groundbreaking trials shaping the modern era of high-dose therapy in myeloma. Proud to see this legacy highlighted in ⁦Blood Cancer Journal⁩ , showcasing how IFM research has set global standards for myeloma care.